missing translation for 'onlineSavingsMsg'
Learn More

Human Siglec-3/CD33 (Research Grade Gemtuzumab Biosimilar) Alexa Fluor 488-conjugated Antibody, R&D Systems™

Human Monoclonal Antibody

Brand:  R&D Systems FAB9635G-100UG

Product Code. 18164261

  • € 558.00 / 100µg

Please to purchase this item. Need a web account? Register with us today!

This item is not returnable. View return policy

Description

Description

Siglec-3/CD33 Monoclonal specifically detects Siglec-3/CD33 in Human samples. It is validated for Flow Cytometry.
TRUSTED_SUSTAINABILITY
Specifications

Specifications

Siglec-3/CD33
Monoclonal
Alexa Fluor 488
Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.
Human
Protein A or G purified from cell culture supernatant
Primary
Detects human Siglec-3/CD33 based on Gemtuzumab therapeutic antibody. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Gemtuzumab. This product is for research use only.
Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 degreesC as supplied.
IgG1
Flow Cytometry
Hu9a
Flow Cytometry 0.25-1μg/106 cells
CD33, CD33 antigen, CD33 antigen (gp67), CD33 molecule, FLJ00391, gp67, myeloid cell surface antigen CD33, p67, sialic acid binding Ig-like lectin 3, Sialic acid-binding Ig-like lectin 3, Siglec3, SIGLEC-3, SIGLEC3gp67
Human Siglec-3/CD33
100 μg
945
Human
Supernatant
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.